2 (1H))-QUINOLINONE,6-(AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL)-4-(3-CHLOROPHENYL)-1-METHYL-,(+)-
Acute Myeloid Leukemia With Abnormal Bone Marrow Eosinophils Inv(16)(P13q22) Or T(16;16)(P13;Q22)
Explore 8 assets in Acute Myeloid Leukemia With Abnormal Bone Marrow Eosinophils Inv(16)(P13q22) Or T(16;16)(P13;Q22) →Floatz Rating
BBB72/100
Confidence
Indicative
Sponsor
National Cancer Institute (NCI)
Modality
Small molecule
Development Phase
Phase 3
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
61High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT01361464CT.gov Tipifarnib in Treating Older Patients With Acute Myeloid Leukemia | — | Completed | — | — | — |
NCT00602771CT.gov Tipifarnib and Etoposide in Treating Older Patients With Newly Diagnosed, Previously Untreated Acute Myeloid Leukemia | — | Completed | — | — | — |
NCT00383474CT.gov Tipifarnib and Bortezomib in Treating Patients With Acute Leukemia or Chronic Myelogenous Leukemia in Blast Phase | — | Completed | — | — | — |
NCT00112853CT.gov Tipifarnib and Etoposide in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia | — | Completed | — | — | — |
NCT00101296CT.gov Tipifarnib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia | — | Completed | — | — | — |
NCT00096122CT.gov Idarubicin, Cytarabine, and Tipifarnib in Treating Patients With Newly Diagnosed Myelodysplastic Syndromes or Acute Myeloid Leukemia | — | Completed | — | — | — |
NCT00093418CT.gov S0432 Tipifarnib in Treating Older Patients With Acute Myeloid Leukemia | — | Completed | — | — | — |
NCT00093470CT.gov Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission | — | Completed | — | — | — |
NCT00045396CT.gov A Phase II Study Of The Farnesyltransferase Inhibitor ZANESTRA (R115777, NSC #702818, IND #58,359) In Complete Remission Following Induction And/Or Consolidation Chemotherapy In Adults With Poor-Risk Acute Myelogenous Leukemia (AML) And High-Risk Myelodysplasia (MDS) | — | Completed | — | — | — |
NCT00027872CT.gov Tipifarnib in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Acute Myeloid Leukemia With Abnormal Bone Marrow Eosinophils Inv(16)(P13q22) Or T(16;16)(P13;Q22)
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| 2 (1H))-QUINOLINONE,6-(AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL)-4-(3-CHLOROPHENYL)-1-METHYL-,(+)- (this asset) | National Cancer Institute (NCI) | P3 | BBB · 72 |
| Daunomycin | National Cancer Institute (NCI) | P3 | BBB |
| Idarubicin | Bruno C. Medeiros | P2 | BBB |
| Cytarabine | Alice Mims | P3 | BBB |
| Fludarabine | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | P2 | BBB |
| Etoposide | Alice Mims | P3 | BBB |
| Azacitidine | The First Affiliated Hospital of Soochow University | P2 | BBB |
| Mitoxantrone | Alice Mims | P2 | BBB |
| Cyclosporin A | National Cancer Institute (NCI) | P3 | BBB |
+42 more in the Acute Myeloid Leukemia With Abnormal Bone Marrow Eosinophils Inv(16)(P13q22) Or T(16;16)(P13;Q22) cohort
Other indications for 2 (1H))-QUINOLINONE,6-(AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL)-4-(3-CHLOROPHENYL)-1-METHYL-,(+)-
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Acute Monocytic Leukemia | — | P2 | BBB · 74 |
| Acute Megakaryoblastic Leukemia | — | P2 | BBB · 72 |
| Acute Myeloid Leukemia With 11q23 Abnormalities | — | P3 | BBB · 72 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. 2 (1H))-QUINOLINONE,6-(AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL)-4-(3-CHLOROPHENYL)-1-METHYL-,(+)- in Acute Myeloid Leukemia With Abnormal Bone Marrow Eosinophils Inv(16)(P13q22) Or T(16;16)(P13;Q22). Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/2-1h-quinolinone6-amino4-chlorophenyl1-methyl-1h-imidazol-5-ylmethyl-4-3-chlorophenyl-1-methyl-acute-myeloid-leukemia-with-abnormal-bone-marrow-eosinophils-inv16p13q22-or-t1616p13q22
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →